title: Quality indicators in breast cancer care.
abstract: To define a set of quality indicators that should be routinely measured and evaluated to confirm that the clinical outcome reaches the requested standards, Eusoma has organised a workshop during which twenty four experts from different disciplines have reviewed the international literature and selected the main process and outcome indicators available for quality assurance of breast cancer care. A review of the literature for evidence-based recommendations have been performed by the steering committee. The experts have identified the quality indicators also taking into account the usability and feasibility. For each of them it has been reported: definition, minimum and target standard, motivation for selection and level of evidence (graded according to AHRO). In overall 17 main quality indicators have been identified, respectively, 7 on diagnosis, 4 on surgery and loco-regional treatment, 2 on systemic treatment and 4 on staging, counselling, follow-up and rehabilitation. Breast Units in Europe are invited to comply with these indicators and monitor them during their periodic audit meetings.
authors.affiliation: Eusoma, Florence, Italy. secretariat@eusoma.org
authors.forename: M Rosselli
authors.initials: MR
authors.lastname: Del Turco
authors.forename: A
authors.initials: A
authors.lastname: Ponti
authors.forename: U
authors.initials: U
authors.lastname: Bick
authors.forename: L
authors.initials: L
authors.lastname: Biganzoli
authors.forename: G
authors.initials: G
authors.lastname: Cserni
authors.forename: B
authors.initials: B
authors.lastname: Cutuli
authors.forename: T
authors.initials: T
authors.lastname: Decker
authors.forename: M
authors.initials: M
authors.lastname: Dietel
authors.forename: O
authors.initials: O
authors.lastname: Gentilini
authors.forename: T
authors.initials: T
authors.lastname: Kuehn
authors.forename: M P
authors.initials: MP
authors.lastname: Mano
authors.forename: P
authors.initials: P
authors.lastname: Mantellini
authors.forename: L
authors.initials: L
authors.lastname: Marotti
authors.forename: P
authors.initials: P
authors.lastname: Poortmans
authors.forename: F
authors.initials: F
authors.lastname: Rank
authors.forename: H
authors.initials: H
authors.lastname: Roe
authors.forename: E
authors.initials: E
authors.lastname: Scaffidi
authors.forename: J A
authors.initials: JA
authors.lastname: van der Hage
authors.forename: G
authors.initials: G
authors.lastname: Viale
authors.forename: C
authors.initials: C
authors.lastname: Wells
authors.forename: M
authors.initials: M
authors.lastname: Welnicka-Jaskiewicz
authors.forename: Y
authors.initials: Y
authors.lastname: Wengstöm
authors.forename: L
authors.initials: L
authors.lastname: Cataliotti
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy*; D055088:Early Detection of Cancer; D005260:Female; D005817:Genetic Counseling; D006300:Health Services Misuse; D006801:Humans; D008134:Long-Term Care / Q000592:standards; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging / Q000592:standards; D010348:Patient Care Team; D011182:Postoperative Care / Q000592:standards; D011300:Preoperative Care / Q000592:standards; D019984:Quality Indicators, Health Care; D014850:Waiting Lists
chemical_list: D000970:Antineoplastic Agents